Raymond James Keeps Their Hold Rating on Abiomed (ABMD)


In a report released yesterday, Jayson Bedford from Raymond James maintained a Hold rating on Abiomed (ABMD). The company’s shares closed last Thursday at $355.13, close to its 52-week high of $387.40.

According to TipRanks.com, Bedford is a 5-star analyst with an average return of 16.3% and a 71.7% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Merit Medical Systems, and Tandem Diabetes Care.

The word on The Street in general, suggests a Hold analyst consensus rating for Abiomed with a $341.25 average price target, which is a 0.4% upside from current levels. In a report released yesterday, BTIG also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Based on Abiomed’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $210 million and net profit of $62.21 million. In comparison, last year the company earned revenue of $205 million and had a net profit of $13.07 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded in 1981 and is headquartered in Danvers, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts